Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2020-10-31
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Describe patient demographic and clinical characteristics
* Describe treatment patterns
* Describe effectiveness outcomes
* Evaluate tumor response
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
NCT04150029
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230
Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML
NCT05048615
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
NCT03226418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AML
Patients diagnosed with AML
azacitidine
Patients taking azacitidine
venetoclax
patients taking venetoclax
glasdegib
patients taking glasdegib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
azacitidine
Patients taking azacitidine
venetoclax
patients taking venetoclax
glasdegib
patients taking glasdegib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Receipt of non-intensive therapy at any point during first line therapy following initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of the following agents, alone or in combination with any other agent:
1. AZA
2. GLAS
3. VEN
3. Age ≥18 years at initial diagnosis of AML.
Exclusion Criteria
1\. Record of 1 or more of the following confounding diagnoses at any point before or after AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1371038
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.